Baseline demographic and clinical characteristics for all study patients
| Characteristic at ART initiation | N | |
|---|---|---|
| Median age in months (IQR) | 494 | 7.3 (4.0–13.4) |
| Male gender (%) | 494 | 233 (47.2) |
| Median WAZ (IQR) | 448 | −2.48 (−3.85 to −0.91) |
| Median CD4 cell count (IQR) | 439 | 757 (385–1404) |
| Median CD4% (IQR) | 431 | 17.3 (11.1–26.4) |
| Severe immune suppression (%) | 431 | 295 (68.5) |
| Median log10 (VL) (IQR) | 379 | 5.87 (5.20–6.45) |
| IPT | ||
| Number of patients prescribed any IPT (%) | 104 (21.1) | |
| Total number of courses | 127 | |
| Median duration of course in months (IQR) | 5.5 (3.1–6.4) | |
ART, antiretroviral therapy; IPT, isoniazid preventive therapy; VL, HIV viral load; WAZ, weight-for-age Z score.